Latest news

• Biogen’s Vumerity recommended by CHMP in MS

  The Committee for Medicinal Products for Human Use (CHMP) has recommended Vumerity (diroximel fumarate) for patients with relapsing-remitting multiple sclerosis (RRMS) in the European Union. ... The active ingredient, monomethyl fumarate, reduces the

• Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment

  Orelabrutinib will fit neatly into Biogen’s MS portfolio, which includes Tecfidera (dimethyl fumarate), Tysabri (natalizumab) and Vumerity (diroximel fumarate).

• Biogen reveals new data for MS therapies Tysabri and Vumerity

  In addition to the Tysabri data, Biogen also disclosed findings on the use of Vumerity (diroximel fumarate) in a real-world setting.

• Biogen triumphs over Mylan’s Tecfidera patent challenge

  The challenge from Mylan focused on Biogen’s ‘514 patent on Tecfidera (dimethyl fumarate) , which is due to expire in 2028. ... Biogen does, however, have its own next-generation MS treatment – Vumerity (diroximel fumarate) – which was recently

• Biogen under fire over $88,000 Vumerity annual price

  Biogen and partner Alkermes scored FDA approval for Vumerity (diroximel fumarate) on the 30 October for the treatment of relapsing forms of MS. ... In comparison, Biogen’s older oral MS drug Tecfidera (dimethyl fumarate) entered the market with a price